Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Dec;6(Suppl 2):S120.
doi: 10.21037/atm.2018.12.25.

Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle?

Francesco Passiglia  1 , Silvia Novello  1
Affiliations
Editorial

Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle?

Francesco Passiglia et al. Ann Transl Med. 2018 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Comment on

  • First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
    Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. Horn L, et al. N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280641 Clinical Trial.

References

    1. Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med 2018;379:2220-9. 10.1056/NEJMoa1809064 - DOI - PubMed
    1. Bunn PA, Minna JD, Augustyn A, et al. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol 2016;11:453-74. 10.1016/j.jtho.2016.01.012 - DOI - PMC - PubMed
    1. Roberts WK, Deluca IJ, Thomas A, et al. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J Clin Invest 2009;119:2042-51. - PMC - PubMed
    1. Peifer M, Fernández-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012;44:1104-10. 10.1038/ng.2396 - DOI - PMC - PubMed
    1. Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016;17:883-95. 10.1016/S1470-2045(16)30098-5 - DOI - PubMed